Craig Coburn, Ph.D., is Silverback’s vice president of chemistry. Dr. Coburn has over 25 years of drug discovery experience as a medicinal chemist. After spending nearly 20 years at Merck Research Labs, where he was a senior investigator, he went on to serve as vice president of medicinal chemistry at WuXi AppTec and later co-founded Maverix Oncology. During his career, he has authored or co-authored over 40 publications and 80 patents. Dr. Coburn received the American Chemical Society’s “Hero of Chemistry” Award for his contributions to the discovery of HCV HS5A replication complex inhibitor elbasvir (marketed as Zepatier® in combination with grazoprevir for the treatment of hepatitis C). Prior to joining Merck, he was an NSF postdoctoral fellow at Memorial Sloan-Kettering Cancer Center, and received his Ph.D. in organic chemistry from Brown University.